Regeneron Pharmaceuticals, Inc.
REGN
$766.66
-$24.15-3.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.65B | 3.56B | 3.49B | 2.95B | 3.61B |
| Total Other Revenue | 238.60M | 198.20M | 183.90M | 81.90M | 179.40M |
| Total Revenue | 3.88B | 3.75B | 3.68B | 3.03B | 3.79B |
| Cost of Revenue | 2.21B | 2.00B | 1.95B | 1.79B | 1.98B |
| Gross Profit | 1.67B | 1.76B | 1.72B | 1.24B | 1.81B |
| SG&A Expenses | 775.00M | 657.80M | 634.20M | 633.00M | 792.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | -10.00M | -- | -- | -- |
| Total Operating Expenses | 2.99B | 2.64B | 2.59B | 2.42B | 2.77B |
| Operating Income | 898.60M | 1.11B | 1.09B | 604.00M | 1.02B |
| Income Before Tax | 1.04B | 1.76B | 1.52B | 905.00M | 958.10M |
| Income Tax Expenses | 199.10M | 303.30M | 127.10M | 96.30M | 40.40M |
| Earnings from Continuing Operations | 844.60M | 1.46B | 1.39B | 808.70M | 917.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 844.60M | 1.46B | 1.39B | 808.70M | 917.70M |
| EBIT | 898.60M | 1.11B | 1.09B | 604.00M | 1.02B |
| EBITDA | 1.04B | 1.25B | 1.22B | 730.90M | 1.15B |
| EPS Basic | 8.21 | 14.09 | 13.24 | 7.58 | 8.53 |
| Normalized Basic EPS | 12.39 | 7.65 | 7.61 | 4.55 | 6.98 |
| EPS Diluted | 7.86 | 13.62 | 12.81 | 7.27 | 8.07 |
| Normalized Diluted EPS | 11.86 | 7.40 | 7.36 | 4.37 | 6.60 |
| Average Basic Shares Outstanding | 102.90M | 103.60M | 105.10M | 106.70M | 107.60M |
| Average Diluted Shares Outstanding | 107.50M | 107.20M | 108.60M | 111.20M | 113.80M |
| Dividend Per Share | 0.88 | 0.88 | 0.88 | 0.88 | -- |
| Payout Ratio | 10.98% | 6.25% | 6.65% | 11.60% | -- |